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Abstract: Chronic obstructive pulmonary disease (COPD) is a leading cause of disability in 
all its stages, and death in patients with moderate or severe obstruction. At present, COPD is 
suboptimally managed; current health is often not measured properly and hardly taken into 
account in management plans, and the future risk for patients with regard to health status and 
quality of life is not being evaluated. This review addresses the effect of COPD on the lives 
of patients and examines ways in which existing assessment tools meet physicians’ needs for 
a standardized, simple method to measure consistently the full impact of COPD on patients 
in routine clinical practice. Current assessment of COPD severity tends to focus on airflow 
limitation, but this does not capture the full impact of the disease and is not well correlated 
with patient perception of symptoms and health-related quality of life. Qualitative studies have 
demonstrated that patients usually consider COPD impact in terms of frequency and severity 
of symptoms, and physical and emotional wellbeing. However, patients often have difficulty 
expressing their disease burden and physicians generally have insufficient time to collect this 
information. Therefore, it is important that methods are implemented to help generate a more 
complete understanding of the impact of COPD. This can be achieved most efficiently using 
a quick, reliable, and standardized measure of disease impact, such as a short questionnaire 
that can be applied in daily clinical practice. Questionnaires are precision instruments that 
contribute sensitive and specific information, and can potentially help physicians provide 
optimal care for patients with COPD. Two short, easy-to-use, specific measures, ie, the COPD 
Assessment Test and the Clinical COPD Questionnaire, enable physicians to assess patients’ 
health status   accurately and improve disease management. Such questionnaires provide important 
measurements that can assist primary care physicians to capture the impact of COPD on patients’ 
daily lives and wellbeing, and improve long-term COPD management.
Keywords: chronic obstructive pulmonary disease, COPD assessment test, disease management, 
health status, quality of life, questionnaire
Background
Chronic obstructive pulmonary disease (COPD) is a major public health problem 
of high and increasing prevalence,1–5 and is a leading cause of disability in all its 
stages6,7 and death in patients with moderate or severe obstruction.8–10 COPD imposes 
a profound burden on patients, including medical emergencies, hospitalizations, work 
absenteeism, and activity limitations. Ultimately, this has a significant physical and 
emotional impact on patients.11
COPD, as defined by airflow limitation, is often underdiagnosed12–14 and 
undertreated,15 leading to poor quality of life for patients.16 Current assessments of International Journal of COPD 2011:6
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Figure 1 Symptom frequency in individuals with COPD (evaluation of worst three-
month period in past year). Patients participating in the Confronting COPD in 
America survey were asked about the frequency of their symptoms during their 
worst three-month period in the past year (ie, “Has there been any three-month 
period in the past year when you experienced … [read item] – every day, most days 
a week, a few days a week, a few days a month, less than that?”). A high proportion 
of patients reported that they frequently experienced specific disease-associated 
outcomes during their worst period in the past year.36 
Reproduced with permission from GlaxoSmithKline.
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COPD severity focus on the amount of air that patients 
can forcibly exhale from their lungs in the first second of 
a forced exhalation (FEV1), but this alone does not capture 
the full impact of the disease.17 As a consequence, patients 
with COPD are often suboptimally managed.18,19 The future 
risk for patients with COPD with regard to health status and 
quality of life is not currently being evaluated routinely, but 
it is likely that this will provide a marker of both current 
impact and future risk in these patients.20–24
Improved COPD management requires a range of patient 
assessments, including lung function, exacerbation episodes, 
exercise tolerance, and impact on health status. However, 
patients often have difficulty expressing the burden of their 
disease and physicians generally do not have sufficient time 
to collect this information. Therefore, it is important that 
methods are implemented to enable clinicians to reach a more 
complete understanding of the impact of the disease on their 
patients and identify specific needs. The most efficient way 
to achieve this is to use a quick, reliable, and standardized 
measure of disease impact, such as a short questionnaire, 
that can be applied in daily clinical practice to provide 
physicians with additional useful information. Validated 
patient-reported outcomes, eg, measurements of health 
  status (health-related quality of life [HRQoL]), or functional 
status are now   recognized as being key in capturing the 
patient’s experience of important aspects of health in chronic 
disease.25 Use of these measures will enable physicians to 
determine what is really important to the individual patient 
and highlight differences between patients.
In conjunction with patient-reported measures, health 
care systems need to be more organized and focused towards 
meeting the current and future needs of patients with 
COPD. Patients with chronic disease require both regular 
clinician assessments and self-management. Application 
of the chronic care model, which includes fundamental 
  elements (eg, the community, health care system, and patient 
  self-management) needed to support high-quality care for 
patients with chronic disease, could potentially improve 
COPD management.26–28
The management of COPD is now directed towards 
symptomatic benefit, in terms of improved HRQoL and 
exercise tolerance, and risk reduction (eg, exacerbations, 
hospital admissions, and death). Assessment of COPD risk 
can now be done in routine clinical practice using simple 
multidimensional prognostic scaling systems, such as the 
DOSE index.29 The aim of this review, however, is to address 
the impact of COPD on patients’ lives and to discuss ways in 
which the new assessment tools can meet physicians’ needs 
for a standardized, simple method to measure consistently 
the full impact of COPD on patients in routine clinical 
practice.
Measuring impact of COPD  
on patients
The burden of COPD on patients and their families is 
high.13,30–32 Furthermore, it is not limited to patients with 
severe COPD, but is also very prominent in younger patients 
with only mild or moderate airway obstruction, limit-
ing them in their daily lives.33 In general, patients have a 
restricted understanding of both the extent of their loss of 
pulmonary function and the severity of their COPD. In the 
Confronting COPD International Survey, patients’ percep-
tions of the severity of their COPD did not consistently 
correspond with the degree of severity indicated by the 
Medical Research Council (MRC) dyspnea (breathlessness) 
scale.16 In   addition, most patients do not appear to place 
the same level of importance on their exacerbation epi-
sodes as health care providers,34 and a recent study showed 
that patients   generally report smaller changes in HRQoL 
outcome measures as more clinically meaningful than do 
physicians.35 Thus, the   provision of measures to document 
clinical outcomes can help both patients and health care 
providers improve their knowledge about the impact of 
COPD on patient health.
Surveys have indicated that patients usually consider the 
impact of COPD in terms of symptom frequency and severity, 
and physical and emotional wellbeing.16 In the Confronting 
COPD in America survey, 90% of individuals with COPD 
experienced symptoms either every day or most days during 
their worst three-month period in the past year (Figure 1).36 International Journal of COPD 2011:6
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Figure 2 Relationship between health status as measured by the SGRQ, and Fev1 
and GOLD stage. Patients’ perception of symptoms and health-related quality of 
life, as assessed by the SGRQ, were not well correlated with objective pulmonary 
function measurements, such as Fev  1 and GOLD stage.
Adapted  from  Jones  Pw.  Health  status  measurement  in  chronic  obstructive 
pulmonary disease. Thorax. 2001;56:880–887 with permission from the BMJ Publishing 
Group Limited.17
Abbreviations: SGRQ, St George’s Respiratory Questionnaire; Fev1, forced expiratory 
volume in one second; GOLD, Global Initiative for Chronic Obstructive Lung Disease.
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Also, patients use language such as “good” and “bad” days 
to define how COPD influences their HRQoL, so patients’ 
self-reported assessments are important when evaluating the 
intensity of symptoms, such as dyspnea and fatigue, and their 
impact on HRQoL.37
Changing health status
A study in patients with stable COPD showed that changes 
in health status assessed by patient-reported measures 
(eg, the St George’s Respiratory Questionnaire [SGRQ], 
Chronic   Respiratory Questionnaire [CRQ], MRC dyspnea 
scale, and the Hospital Anxiety and Depression Scale 
[HADS])   worsened significantly over time.38 However, 
deteriorations in patient-reported outcomes (eg, symptoms, 
limitation of daily activities, and wellbeing) showed only 
a weak correlation with changes in physiological indices 
such as FEV1 and maximal oxygen uptake measured at 
peak exercise.38 Those authors concluded that to capture the 
overall deterioration in patients’ health status due to COPD, 
patient-reported outcomes should be followed independently 
of physical outcomes.38
Challenges in providing chronic care 
for patients with COPD
During a consultation, patients tend to understate their 
disease severity, under-report COPD exacerbations, and do 
not   convey the impact of the disease on their quality of life. 
In addition, patients often only present to their physicians 
when their condition has progressed significantly leading 
to a reduced HRQoL.14,39 Consequently, there is a need 
to assess patients’ health status to enable optimal disease 
management.
Clinical assessment questionnaires 
in COPD
Physicians need to consider several factors when assessing 
patients with COPD. The impact of COPD depends not only 
on the degree of airflow limitation but also on the   severity 
of symptoms, systemic effects, and any comorbidities 
present.2,31 When a patient experiences an exacerbation 
they often require several weeks of recovery;24 sustained 
worsening of symptoms can also have a significant impact on 
patients’ HRQoL and mortality.40–44 Importantly,   reductions 
in objective pulmonary function measurements, such as 
FEV1, are not well correlated with patients’ perception of 
symptoms and HRQoL (Figure 2).17,45 When managing 
patients with COPD it is therefore necessary to measure both 
pulmonary function and HRQoL.
Physicians require help in realizing the full impact of 
COPD on their patients. Qualitative studies showed that 
patients with COPD have difficulty placing themselves 
along a continuum of disease severity and relating their 
severity to that of other patients with COPD. During devel-
opment of the COPD Assessment Test (CAT), patients indi-
cated that they would like to have a method available that 
would allow them to both assess their own disease severity 
and communicate this information to their physicians.46
Standardized assessments, beyond peak airflow 
(maximally forced expiration initiated at full inspiration) 
currently used to assess patients in clinical practice 
evaluate multidimensional domains (symptoms, physical, 
psychological, and social) affected by COPD. Examples 
of disease-specific instruments include the MRC dyspnea 
scale, the Clinical COPD Questionnaire (CCQ), and the 
CAT.46–48 These measures can be assessed in terms of their 
relative   reliability, validity, responsiveness, acceptability, 
and   feasibility in everyday clinical practice.25 Other 
  questionnaires such as the SGRQ, CRQ, and Short Form 
36-item Health Survey (SF-36) comprise many more 
  questions and consequently are not suitable for use in daily 
clinical practice, so these questionnaires are not discussed 
further. A comprehensive review of available questionnaires 
is currently being undertaken by the International Primary 
Care Respiratory Group (www.theipcrg.org/).
Questionnaires are precision instruments that can provide 
sensitive and specific information and, if sufficiently short 
and simple, can enable physicians in routine clinical practice 
to assess the health status of their patients accurately, thereby 
allowing improved COPD management.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
292
Jones et al
CLINICAL COPD QUESTIONNAIRE  
©
Information:
Prof. T.van der Molen, MD PhD
Dept. Of General Practice
University Medical Center Groningen
Postbus 196
9700 AD Groningen
The Netherlands
Fax: +31 503632964
E-mail:  t.van.der.molen@med.umcg.nl
Internet: www.ccq.nl
1999
Figure 3 The clinical COPD questionnaire. 
Reproduced with permission from Thys van der Molen.
Patient number:___________
Date:_____________________
CLINICAL COPD QUESTIONNAIRE
Please circle the number of the response that best describes how you have been feeling during the past week. 
(Only one response for each question).
On average, during the past week, 
how often did you feel:
never hardly 
ever
a few 
times
several 
times
many 
times
a great 
many times
almost 
all the time
1. Short of breath at rest? 0 1 2 3 4 5 6
2. Short of breath doing physical activities? 0 1 2 3 4 5 6
3.   Concerned about getting 
a cold or your breathing getting worse?
0 1 2 3 4 5 6
4.   Depressed (down) because 
of your breathing problems?
0 1 2 3 4 5 6
In general, during the past week, 
how much of the time:
5. Did you cough? 0 1 2 3 4 5 6
6. Did you produce phlegm? 0 1 2 3 4 5 6
On average, during the past week, 
how limited were you in these activities 
because of your breathing problems:
not limited 
at all
very slightly 
limited
slightly 
limited
moderately 
limited
very 
limited
extremely 
limited
totally limited/ 
or unable to do
7.   Strenuous physical activities (such as 
climbing stairs, hurrying, doing sports)?
0 1 2 3 4 5 6
8.   Moderate physical activities (such as 
walking, housework, carrying things)?
0 1 2 3 4 5 6
9.   Daily activities at home (such as 
dressing, washing yourself)?
0 1 2 3 4 5 6
10.   Social activities (such as talking, being 
with children, visiting friends/relatives)?
0 1 2 3 4 5 6
©  The  CCQ  is  copyrighted.  It  may  not  be  altered,  sold  (paper  or  electronic),  translated  or  adapted  for  another  medium  without  the  permission  of   
T. van der Molen, Dept. of General Practise, University Medical Center Groningen, Postbus 196, 9700 AD Groningen, The Netherlands.International Journal of COPD 2011:6
Figure 4 The COPD assessment test. 
Reproduced with permission from GlaxoSmithKline.
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Medical research council dyspnea scale
The MRC dyspnea scale, recommended by the Global 
  Initiative for Chronic Obstructive Lung Disease (GOLD)2 
and other national guidelines, was developed by Fletcher et al 
while studying the respiratory problems of Welsh coalminers 
in the 1940s.48,49 It is short (comprises five dyspnea items) 
and has been in use for many years for grading the effect of 
breathlessness on daily activities. It is simple to administer 
because it allows patients to indicate the extent to which 
their breathlessness affects their mobility. However, it only 
measures one aspect of the patient experience (ie, perceived 
respiratory disability) and is poorly responsive to change.
Clinical COPD questionnaire
The CCQ (Figure 3) consists of three domains and 10 items, ie, 
symptoms (four items), functional state (four items), and mental 
state (two items). All scores range from 0–6 (0, no impairment).47 
The CCQ was developed in consultation with 32 patients in 
two countries, and item reduction performed in collaboration 
with 79 clinicians worldwide. Patients can complete the CCQ 
quickly (in approximately two minutes) and it is straightforward 
to score; this allows data to be instantly collected and processed, 
enabling its use in everyday practice, clinical trials, and quality-
of-care monitoring. Three studies in the Netherlands, Italy, and 
Sweden provided strong supporting evidence for the reliability, 
validity, and responsiveness of the CCQ.47,50,51 A change in the 
total CCQ score of $0.4 from one patient visit to the next is 
considered to be significant (ie, the minimum clinically impor-
tant difference).52 The CCQ is freely available (in 53 languages) 
for use in clinical practice (www.ccq.nl).
COPD assessment test
The CAT (Figure 4) is a short (eight-item) and simple-
    to-  administer patient-completed questionnaire designed 
for   routine use in clinical practice. It covers a wide range 
of effects of COPD, including cough and sputum, chest 
symptoms, activity limitation, sleep, fatigue, and confidence 
leaving home. Patients can complete the CAT quickly 
(in approximately two minutes) by themselves in the 
  doctor’s waiting room. Development of the CAT involved 
consultation with a large number of patients at each stage of 
the process. Items covered in the CAT can help physicians 
measure the overall impact that COPD is having on patient 
wellbeing and daily life. Thus, the CAT provides a holistic 
measure of COPD health status;46 it should facilitate a fact-
based, physician-patient dialog and improve communication 
to present a common understanding and grading of the impact 
of COPD. It is supported by strong evidence for reliability 
and by preliminary data for construct and discriminant 
validity;46 additional validity analyses are ongoing. The 
minimum   clinically important difference in CAT score is 
yet to be established formally,53 but based upon mapping 
from the SGRQ at a population level it will be approximately 
1.6 units. At the individual patient level, a change in CAT 
score of $2 units will be clinically significant. The CAT is 
freely available (although GlaxoSmithKline owns the copy-
right to protect it from unauthorized changes) for use in daily 
clinical practice (www.catestonline.org).
Summary
An increased understanding of the full impact of COPD on 
patients and their carers should enable physicians to provide 
targeted intervention and improve patients’ HRQoL.
Care for patients with COPD can be optimized best by 
use of reliable, standardized measurements of overall disease 
impact. The measures should be appropriate to the question 
being addressed, sensitive to changes that are relevant to 
patients, capable of providing physicians with meaningful 
scores, and acceptable to both patients and health care 
providers.54 The questionnaires reviewed here have those 
attributes and are quick and easy to use during consultations. 
Incorporation of questionnaires such as these into the con-
sultation process will enable improved patient-physician 
partnership decision-making, help prioritize patients for 
primary care review, and drive effective management of 
patients with COPD.
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